China Manufacturing Landscape for Milrinone (CAS 78415-72-2)
Milrinone, the phosphodiesterase III inhibitor used in acute heart failure management, represents a critical API in China’s cardiovascular pharmaceutical manufacturing portfolio. Our cquality-controlled production facility in Jiangsu Province operates a dedicated synthesis line for Milrinone API, supplying injectable formulation manufacturers across North America, Europe, Japan, and emerging markets. As a direct manufacturer source, we provide pharmaceutical companies with supply chain transparency and pricing that reflects actual manufacturing costs.
China’s position in Milrinone production has strengthened considerably as domestic manufacturers have invested in the quality infrastructure necessary to meet stringent regulatory expectations for injectable-grade APIs. Our facility has undergone successful inspections by multiple international regulatory agencies, confirming our capability to produce APIs suitable for parenteral dosage forms.
Manufacturing Process & Facility
Our Milrinone synthesis employs a well-characterized multi-step chemical process starting from 2-methyl-3-amino-4-cyanopyridine. The synthesis involves key transformations including cyclization, amination, and final purification to yield pharmaceutical-grade Milrinone with the high purity required for injectable applications. Critical process parameters are controlled through automated systems with real-time analytical monitoring.
Facility highlights:
- Dedicated production suites for injectable-grade API manufacturing
- ISO Class 7 cleanroom environments for final isolation and packaging
- Glass-lined and Hastelloy reactors (200L to 3000L) for corrosion-resistant processing
- Automated process control with 21 CFR Part 11 compliant data systems
- Annual production capacity: 3 metric tons of Milrinone API
- Dedicated microbiology laboratory for endotoxin and bioburden testing
Our injectable-grade API production follows enhanced pharmaceutical quality protocols including additional environmental monitoring, heightened personnel gowning requirements, and validated cleaning procedures with limits specific to parenteral applications.
Quality Standards & Multi-Pharmacopeial Compliance
Milrinone API from our facility meets the stringent quality requirements for injectable formulations, complying with USP, EP, and JP specifications:
| Parameter | Specification | Test Method |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual |
| Identification | Positive by IR, HPLC, UV | IR/HPLC/UV |
| Assay (dried basis) | 98.5–101.0% | HPLC |
| Related Substances (total) | ≤0.5% | HPLC |
| Any Single Impurity | ≤0.10% | HPLC |
| Residual Solvents | Meets ICH Q3C | GC-HS |
| Elemental Impurities | Meets ICH Q3D (parenteral limits) | ICP-MS |
| Bacterial Endotoxins | ≤0.5 EU/mg | LAL (kinetic turbidimetric) |
| Bioburden | ≤10 CFU/g | Membrane filtration |
| Particle Size (D90) | ≤30 μm | Laser diffraction |
Regulatory Documentation
Our Milrinone API regulatory dossier is designed to support customer filings for injectable drug products:
- US FDA Drug Master File (Type II) — active, regularly updated
- EU CEP application submitted and under review
- China NMPA registration for API production
- Complete process validation and cleaning validation reports
- ICH Q1A stability data with 36-month long-term and 6-month accelerated results
- Forced degradation studies demonstrating stability-indicating analytical methods
- Nitrosamine risk assessment per FDA/EMA guidance
- Elemental impurity risk assessment per ICH Q3D for parenteral route
We support customer regulatory teams throughout the filing and review process, providing timely responses to agency queries and additional data requests.
Packaging & Logistics
Milrinone packaging is designed for injectable-grade API with enhanced protection requirements:
- Primary: Triple-layer aluminum foil bags, nitrogen-purged, heat-sealed
- Secondary: HDPE drums with tamper-evident seals (1 kg, 5 kg, 10 kg, 25 kg)
- All packaging materials qualified for pharmaceutical use with extractables data
- Storage: Room temperature (15-25°C), protected from light
- Shelf life: 36 months from manufacture date
We ship worldwide with pharmaceutical-qualified logistics providers. Temperature-monitored shipments are standard for all injectable-grade API exports. Incoterms available: FOB, CIF, DDP.
Competitive Pricing & Supply Reliability
Our Milrinone pricing reflects the efficiencies of a specialized manufacturer with optimized synthesis and purification processes:
- Optimized synthetic route achieving high overall yields and minimal waste
- In-house production of key intermediates ensuring supply security
- Dedicated production capacity with scheduled campaigns for major customers
- Emergency supply capability with expedited production timelines available
Order flexibility ranges from 100g sample quantities to annual supply contracts of several hundred kilograms. We offer competitive pricing with volume incentives and long-term agreement discounts. Contact our cardiovascular API division for detailed quotations and technical information packages.